证券代码：601089 证券简称：福元医药 公告编号：临 2023-031 北京福元医药股份有限公司 第二届监事会第七次会议决议公告 表决情况：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交 2023 年第一次临时股东大会审议，并需由出席股东大会的股东 （包括股东代理人）所持表决权的三分之二以上通过。 具体内容详见公司披露于上海证券交易所网站的《关于变更公司经营范围及修订< 公司章程>并办理工商变更登记的公告》及《北京福元医药股份有限公司章程》。 特此公告。 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 北京福元医药股份有限公司（以下简称"公司"）第二届监事会第七次会议于 2023 年 9 月 6 日以书面等方式发出会议通知，并于 2023 年 9 月 11 日在北京以现场结 合通讯表决的方式召开会议。公司应参加表决的监事 3 名，实际参加表决的监事 3 名， 会议由监事会主席赵嘉女士主持召开。会议召开符合法律法规、《公司法》及《公司章 程》的规定，会议决议合法、有效。 二、监事会会议审议情况 ...

北京福元医药股份有限公司 2023 年第一次临时股东大会会议材料 北京福元医药股份有限公司 2023 年第一次临时股东大会会议材料 2023 年 9 月 北京福元医药股份有限公司 2023 年第一次临时股东大会会议材料 目 录 北京福元医药股份有限公司 2023 年第一次临时股东大会会议议程............................. 2 议案一 关于变更公司经营范围及修订《公司章程》并办理工商变更登记的议案... 3 1 北京福元医药股份有限公司 2023 年第一次临时股东大会会议材料 北京福元医药股份有限公司 2023 年第一次临时股东大会会议议程 一、会议时间：2023 年 9 月 27 日 14 点 30 分 二、会议地点：公司二楼会议室（北京市通州区通州工业开发区广源东街 8 号） 三、会议内容： （一）主持人宣布大会开始，宣布股东到会情况。 （二）推选监票人和计票人。 （三）审议会议议案： | 序号 | 议案名称 | | --- | --- | | | 关于变更公司经营范围及修订《公司章程》并办理工商变更登记的议 | | 1 | | | | 案 | 四、参会股东、股东代表、委托代表对 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 1,629,808,705.94, representing a 5.61% increase compared to the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 250,315,567.56, marking a 21.57% increase year-on-year[21]. - The net profit after deducting non-recurring gains and losses was CNY 243,244,774.92, which is a 26.00% increase compared to the previous year[21]. - The net cash flow from operating activities increased by 41.98% to CNY 281,722,500.95[21]. - The total assets of the company at the end of the reporting period were CNY 4,344,732,277.53, a 0.54% increase from the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were CNY 3,230,241,042.15, reflecting a 1.77% increase year-on-year[21]. - The basic earnings per share for the first half of 2023 were CNY 0.52, down 8.77% from the same period last year[22]. - The weighted average return on net assets decreased by 8.69 percentage points to 7.67%[22]. - The company achieved an investment income of 2,274,851.37 from bank wealth management products[25]. - The company reported a total comprehensive income of ¥252,279,579.43 for the first half of 2023, compared to ¥207,054,971.39 in the previous year, marking an increase of 21.8%[158]. Research and Development - The company is focused on the research and development of drugs and medical devices, with a strong competitive edge and high market recognition[28]. - The company aims to enhance its R&D capabilities by increasing the proportion of innovative drug development and improving the integration of raw material and formulation processes[29]. - The company has a strong R&D reserve with 55 projects in generic drug formulation and 4 in innovative drugs under development[41]. - The company is collaborating with prestigious universities such as Peking University and Tsinghua University to enhance R&D capabilities, with a contract amount of ¥500,000 for a project on carboxymethyl maltose iron[46]. - The company is focusing on the development of innovative drugs, having filed 7 patent applications and advancing 13 nucleic acid drug targets for efficacy evaluation[45]. - The company has established four major technology platforms, including chemical synthesis and oral solid dosage technology, supporting its product development[41]. Market and Sales Strategy - The sales model includes both distribution and direct sales, with a focus on promoting products in domestic and international markets[33]. - The company exports products primarily to regions such as Africa and Southeast Asia, utilizing qualified distributors for overseas sales[33]. - The company has a comprehensive sales network collaborating with major pharmaceutical distribution companies, ensuring stable sales growth[42]. - The company is actively participating in the national centralized procurement program, with a target of 450 drug varieties by the end of 2023[35]. - The company is enhancing its marketing strategy by increasing investment and optimizing marketing models to improve overall efficiency[48]. Environmental Management - The company is committed to safety and environmental management, achieving national-level "Green Factory" status through effective waste control measures[51]. - The company has implemented a comprehensive quality management system to ensure product quality and compliance with regulatory requirements[50]. - The company has implemented measures to ensure that all monitored emissions are within the regulatory limits, demonstrating compliance with environmental standards[87]. - The company has a wastewater treatment capacity of 300 m³/d, operational since 2017, and is currently running normally[90]. - The company has engaged third-party services for monitoring and maintenance of wastewater treatment equipment, ensuring operational efficiency[96]. Risk Management - The company did not report any significant risks that could materially affect its operations during the reporting period[10]. - The company faces risks from intensified market competition, particularly if competitors launch more effective or cost-efficient products[65]. - The company is subject to risks associated with national drug procurement policies, which could lead to slower growth or declines in operating performance if products fail to win bids[66]. - The R&D process for drugs and medical devices is capital-intensive and time-consuming, with risks of failure at various stages[69]. Shareholder and Corporate Governance - The company has committed to a 12-month lock-up period for shares held by supervisors, prohibiting any transfer or management delegation of shares prior to the public offering[112]. - The company will ensure compliance with all applicable laws and regulations regarding shareholding and reduction practices[107]. - The company has ensured full disclosure of all related party transactions as per regulatory requirements, with no undisclosed transactions existing as of the commitment date[116]. - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[73]. - There are no significant lawsuits or arbitration matters during the reporting period[122]. Financial Position - The total liabilities decreased to RMB 1,108,133,998.82 from RMB 1,143,012,517.50, a decline of about 3.05%[150]. - Shareholders' equity increased to RMB 3,236,598,278.71 from RMB 3,178,546,515.68, reflecting a growth of approximately 1.83%[150]. - The company reported a significant increase in long-term investments, with non-current assets totaling RMB 1,075,285,464.90, up from RMB 949,188,283.57, indicating a strategic focus on long-term growth[149]. - The company has made progress in reducing short-term borrowings, which increased to RMB 55,046,013.90 from RMB 40,048,833.34, reflecting a strategic shift in financing[149]. - The company has a total of 8.63 tons of total nitrogen emissions, which is compliant with the standard limit[84].

证券代码：601089 证券简称：福元医药 公告编号：临 2023-029 北京福元医药股份有限公司 关于 2023 年半年度募集资金的存放与实际使用情况 的专项报告 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准北京福元医药股份有限公司首次公 开发行股票的批复》（证监许可[2022]974 号）核准，公司首次向社会公开发行 人民币普通股（A 股）股票共计 12,000 万股，发行价格为每股人民币 14.62 元， 股票发行募集资金总额为人民币 1,754,400,000 元，扣除所有股票发行费用 （ 不 含 增 值 税 ， 包 括 承 销 及 保 荐 费 用 以 及 其 他 发 行 费 用 ） 人 民 币 118,480,188.68 元，实际募集资金净额为人民币 1,635,919,811.32 元。 首次公开发行股票的募集资金于 2022 年 6 月 27 日由中信建投证券股份 有限公司在按规定扣除相关保荐承销费用后划付至公司指定募集资金账户，并 经天健会计师事务所（特殊普通合伙）审验，出具《验资报告》（天健验 [2022]315 号）。 （二）募集资金使 ...

陈劲 李立东 北京福元医药股份有限公司独立董事 关于第二届董事会第六次会议相关事项的独立意见 根据中国证券监督管理委员会《上市公司独立董事规则》《上市 公司治理准则》等法律、法规以及根据《北京福元医药股份有限公司 章程》《北京福元医药股份有限公司独立董事工作制度》等相关规定， 我们作为北京福元医药股份有限公司（以下简称"公司"）的独立董 事，对公司第二届董事会第六次会议相关议案发表如下独立意见： 一、关于2023年半年度募集资金的存放与实际使用情况的独立意 见 经核查，我们认为公司《关于2023年半年度募集资金的存放与实 际使用情况的专项报告》中的募集资金存放和使用相关信息及时、真 实、准确、完整。2023年半年度，公司募集资金的管理和使用符合中 国证券监督管理委员会和上海证券交易所关于上市公司募集资金存 放和使用情况的相关规定，不存在募集资金存放和使用违规的情形。 我们同意本议案。 （以下无正文） （本页无正文，为独立董事关于第二届董事会第六次会议相关事项 的独立意见签署页） 独立董事： 王秀萍 郑晓东 2023 年 08 月 11 日 ____________ ____________ _________ ...

证券代码：601089 证券简称：福元医药 公告编号：临2023-027 北京福元医药股份有限公司 第二届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京福元医药股份有限公司（以下简称"公司"）第二届董事会第六次会议于 2023 年 8 月 1 日以书面及邮件等方式发出会议通知，并于 2023 年 8 月 11 日在北京以现 场结合通讯表决的方式召开会议。会议应参加表决的董事 9 名，实际参加（授权）表 决的董事 9 名，董事石观群先生因公务原因无法出席本次会议，已授权董事胡少羿女 士代为行使表决权。会议由董事长黄河先生主持召开，监事及高级管理人员列席会议。 会议召开符合法律法规、《公司法》及《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于 2023 年半年度报告及摘要的议案》 具体内容详见公司披露于上海证券交易所网站的《2023 年半年度报告》《2023 年半年度报告摘要》。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 （二 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2023-028 北京福元医药股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 北京福元医药股份有限公司（以下简称"公司"）第二届监事会第六次会议于 2023 年 8 月 1 日以书面及邮件等方式发出会议通知，并于 2023 年 8 月 11 日在北京以 现场结合通讯表决的方式召开会议。公司应参加表决的监事 3 名，实际参加表决的监 事 3 名，会议由监事会主席赵嘉女士主持召开。会议召开符合法律法规、《公司法》及 《公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 表决情况：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 (一)公司 2023 年半年度报告的编制和审议程序规范合法，符合法律、法规、公司 章程和公司内部管理制度的各项规定，内容真实、准确、完整。 (二)公司 2023 年半年度报告的内容和格式符合中国证监会和上海证券交易所的各 项规定，所包含的信息真实客观反映了公司 202 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2023-026 北京福元医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 一、 说明会类型 会议召开时间：2023 年 08 月 17 日(星期四) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 10 日(星期四) 至 08 月 16 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ir@foyou.com.cn 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 819,176,868.99, representing a year-on-year increase of 9.56%[5] - The net profit attributable to shareholders for the same period was CNY 113,705,518.99, reflecting a growth of 32.85% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 110,453,764.60, which is an increase of 38.66% year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.24, unchanged from the previous year[6] - The company's net profit for Q1 2023 reached CNY 115,180,784.67, a 34.0% increase compared to CNY 85,993,898.93 in Q1 2022[22] - Operating profit for Q1 2023 was CNY 128,371,945.32, representing a 34.5% increase from CNY 95,402,037.07 in Q1 2022[21] - Total revenue from sales and services amounted to CNY 768,393,348.37, an increase from CNY 698,299,027.48 in Q1 2022[26] - The company reported a total comprehensive income of CNY 115,180,784.67, compared to CNY 85,993,898.93 in the previous year[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,389,551,999.81, an increase of 1.57% from the end of the previous year[6] - The company's cash and cash equivalents amounted to RMB 2,234,007,135.50 as of March 31, 2023, compared to RMB 2,541,250,325.65 at the end of the previous period[16] - Total assets increased to RMB 4,389,551,999.81 as of March 31, 2023, from RMB 4,321,559,033.18 in the previous period, marking a growth of 1.57%[17] - Total liabilities decreased to RMB 1,096,041,312.29 from RMB 1,143,012,517.50, indicating a reduction of 4.12%[18] - The company's equity attributable to shareholders rose to RMB 3,287,522,769.50, up from RMB 3,174,033,863.34, reflecting an increase of 3.57%[18] Cash Flow - The net cash flow from operating activities was CNY 82,973,037.29, showing a decrease of 3.42% compared to the same period last year[5] - Cash flow from operating activities generated CNY 82,973,037.29, slightly down from CNY 85,907,088.90 in the same period last year[26] - The cash and cash equivalents at the end of Q1 2023 were CNY 2,233,696,135.50, down from CNY 2,540,939,325.65 at the beginning of the quarter[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,242[12] - The top shareholder, Xinheng Holdings Group Co., Ltd., held 176,316,354 shares, accounting for 36.7% of the total shares[12] Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 697,038,640.20, up from RMB 654,296,998.45 in Q1 2022, reflecting a year-over-year increase of 6.55%[20] - The company’s total operating expenses increased to CNY 726,393,620.19, up from CNY 626,208,958.59 in the previous year[26] - Research and development expenses increased to CNY 70,612,425.92, up 42.3% from CNY 49,602,481.80 in the previous year[21] - The company incurred financial expenses of CNY -13,068,037.21, compared to CNY -382,589.45 in Q1 2022[21] Market Strategy - The company is focusing on expanding its market presence and enhancing product development strategies in the upcoming quarters[20] Miscellaneous - The weighted average return on equity decreased by 3.30 percentage points to 3.52%[6] - Inventory levels were reported at RMB 340,817,417.24, slightly up from RMB 339,097,725.33, indicating a marginal increase of 0.51%[16] - There are no significant changes in the shareholder structure or related party transactions reported during this period[16] - The company reported non-recurring gains of CNY 3,251,754.39 for the quarter[9] - The company reported a net profit margin improvement, with net profit figures to be detailed in the full report[20]

北京福元医药股份有限公司 关于召开2023年一季报业绩说明会的公告 证券代码：601089 证券简称：福元医药 公告编号：临2023-019 会议召开时间：2023 年 05 月 05 日（星期五）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议问题征集： 投 资 者 可 于 2023 年 05 月 05 日 前 访 问 网 址 https://eseb.cn/145pSmSnM1q 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 举办北京福元医药股份有限公司 2023 年一季报业绩说明会，与投资者进行沟通 和交流，广泛听取投资者的意见和建议。 二、说明会召开的时间、地点和方式 会议召开时间：2023 年 05 月 05 日（星期五）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 三、参加人员 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完 ...